4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review
about
Symptomatic management in multiple sclerosisPharmacological Alternatives for the Treatment of Neurodegenerative Disorders: Wasp and Bee Venoms and Their Components as New Neuroactive ToolsAcrolein-mediated conduction loss is partially restored by K⁺ channel blockersDynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine).Aquatic training in MS: neurotherapeutic impact upon quality of life.Fampridine and quality of life in individuals with multiple sclerosis4-Aminopyridine promotes functional recovery and remyelination in acute peripheral nerve injuryPharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis.Changes in cognition, arm function and lower body function after slow-release Fampridine treatment.Reducing falls and improving mobility in multiple sclerosis.The effect of symptom-controlling medication on gait outcomes in people with multiple sclerosis: a systematic review.Real-life experience with fampridine (Fampyra®) for patients with multiple sclerosis and gait disorders.Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trialPrevalence of Walking-Related Motor Fatigue in Persons With Multiple Sclerosis: Decline in Walking Distance Induced by the 6-Minute Walk Test.Suppression of Inflammatory Demyelinaton and Axon Degeneration through Inhibiting Kv3 Channels.4-Aminopyridine: a pan voltage-gated potassium channel inhibitor that enhances Kv 7.4 currents and inhibits noradrenaline-mediated contraction of rat mesenteric small arteries.An efficient new method for the synthesis of 3-[18 F]fluoro-4-aminopyridine via Yamada-Curtius rearrangement.Experience with fampridine in clinical practice: analysis of a possible marker of clinical response.Fampridine-PR (prolonged released 4-aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous system.Reported direct aminopyridine effects on voltage-gated calcium channels is a high-dose pharmacological off-target effect of no clinical relevance
P2860
Q26779897-1719FC30-5751-4C01-8753-E9F817728158Q26795786-7354DE46-D9C9-4F63-9A42-66B3DB85AF2DQ28829557-3ECE68C2-454D-4E1D-BFC4-01BE0A8D2D9BQ35785851-96066911-6A7F-493F-879E-BE867AA86F9CQ36010444-43C40B54-BFC8-47FE-A1C0-C2F2F3FBBE43Q37092498-9AA28CB6-B544-4521-BD6B-ED7F3CC9E118Q37514791-5074533F-0070-4217-87D3-9FEA136E34E3Q38289267-33177A9D-8071-41E1-BAC6-6956F37473F8Q38429822-DA9D9459-D97A-4837-851E-BD8C7A4F065DQ38479436-9AB514EC-4EEE-4368-986C-27CE2CA44EE6Q38735071-4BB87B3C-6FC9-4631-87A1-D49CBB671B4AQ40670268-BD6C02E2-9197-41D0-BF9B-92755ED2BF81Q41058601-783FA01F-4971-423E-AA29-11D82C0FA54EQ41541763-A2CC16BE-0293-48A5-993F-A90FAEE8572FQ47117550-AE5BDE8A-251C-48B0-81E1-B5CF2DFD6B99Q47443094-7D5A90F3-4596-46E8-9CE5-6DE68C0E72B9Q48132619-C2DB0ECD-D889-4419-A65B-C3B6562377D6Q50971592-4F8BA423-8829-4CEE-898C-BB0239EFBF66Q53200237-4A187AD0-61F2-47E3-9879-8FD703FF7719Q57471361-F99B94EF-CD8C-4CEE-A3BC-5566DFC382F2
P2860
4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review
@ast
4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review
@en
4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review
@nl
type
label
4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review
@ast
4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review
@en
4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review
@nl
prefLabel
4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review
@ast
4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review
@en
4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review
@nl
P2860
P50
P3181
P356
P1476
4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review
@en
P2093
Mads Ravnborg
P2860
P304
P3181
P356
10.1177/1756285613512712
P407
P577
2014-03-01T00:00:00Z